Our Stocks to Watch tomorrow include RELM Holdings Inc. (OTC: RELM), NW Tech Capital Inc. (OTCBB: NWTT), Seamless Corp. (OTCBB: SMWF), Precision Petroleum Corp. (OTCBB: PPTO), Left Behind Games Inc. (OTCBB: LFBG) and AVI BioPharma Inc. (Nasdaq: AVII).
RELM HOLDINGS INCORPORATED (OTC: RELM)
"Up 166.67% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/RELM.php
RELM was incorporated to acquire operating businesses and is now a holding company with a primary focus on financial and information technology services along with real estate. The Company bases its business model on the acquisition of synergistic businesses with the capability to support and compliment its financial and technology products. RELM intends to lead a vertically integrated family of companies that will provide full solutions for its affiliates and clients, such as underwriting, servicing, raising capital, and commercialization, while securitizing and guaranteeing its products in the marketplace. Since 1994 the Company has conceived, designed, and developed innovative, new products that "absorb asset risk."
RELM News:
October 5 - RELM Holdings Inc. Has Purchased 76% of Access Versalign Inc.
RELM Holdings Inc. (OTC: RELM) announces the restructuring of the purchase of Access Versalign Inc. (AVI) and rescinds the planned merger that was announced on May 5, 2009.
Previously, both AVI and RELM agreed to merge through a share exchange; however, it was later determined that the acquisition of a 76% majority interest in AVI would better suit the relationship and planned future acquisitions. AVI shareholders will receive 14.02 shares of RELM in this transaction as was previously announced. AVI is a consolidated subsidiary of RELM and the senior management team of AVI will also continue to oversee the day to day operations of RELM.
As announced earlier, this acquisition will give RELM access to cash flows and expanded business opportunities in the information technology industry. In 2008, on a pro-forma basis, AVI had over $9 million in assets as a consolidated company and generated $2.5 million in revenue with $319,680 in EBITDA. Through the second quarter of 2009 AVI's wholly-owned subsidiary, Versalign Inc., produced total revenue of $1.1 million with an EBITDA of $142,680 and pretax income of $24,245. RELM valued 100% of AVI at $3,196,800 at the end of 2008.
AVI was organized in 2008 and acquired 100% of Versalign on February 20, 2009. Versalign was founded in 1985 and currently provides targeted information technology solutions for corporate, professional and governmental clients in the Mid-Atlantic region. The proprietary BCLOC financing product of $6 million was used to help restructure the Versalign bank loan, which is expected to provide $2.255 million in new working capital and funds to pay off the existing $3.745 million bank loan.
This acquisition increases RELM's employee base to over 25 employees and it expects to bring continued growth because in the beginning of the second quarter of 2009, Access Versalign secured more than $200,000 in incremental business and expects to maintain a positive profit margin throughout the balance of 2009.
ABOUT AVI
AVI was organized in 2008 and in 2009 acquired Versalign Inc., which was founded in 1985 and currently provides targeted Information Technology solutions for corporate, professional and governmental clients in the Mid-Atlantic region. AVI provides RELM with new top management plus it increases the employee base to over 25 employees. This acquisition gives RELM access to cash flows and expanded business opportunities in the information technology industry.
NW TECH CAPITAL INCORPORATED (OTCBB: NWTT)
"Up 150.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/NWTT.php
NW Tech Capital, Inc., a technology consulting and management company, provides services in the areas of wireless, telecommunications, and broadband. Its services include business planning and advisory services; engineering, furnishing, and installation services for WiMAX systems; Internet protocol infrastructure and IMS applications for service providers; managed services to operate and maintain WiMAX networks; and operations support and customer care systems to support partners’ business operations integrated with operating assets in an user interface. It markets its products and services to various agencies, companies, and institutions. The company was founded in 1996. The company was formerly known as Cybertel Communications Corp. and changed its name to CyberTel Capital Corporation in 2004. Further, it changed its name to NW Tech Capital, Inc. in January 2008. NW Tech Capital is based in
NWTT News:
October 3 - NW Tech Capital, Inc. Files Annual Report
Visit http://bit.ly/4WFLe to view the most recent annual financial report for NW Tech Capital, Inc. (OTCBB: NWTT), a technology consulting and management company.
SEAMLESS CORPORATION (OTCBB: SMWF)
"Up 100.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/SMWF.php
Seamless Corporation develops and markets hardware and software products manufactured by Seamless and others and sells those products through its subsidiary, Seamless Sales LLC.
SMWF News:
October 2 - Seamless Corp. Re-Opens Its eCommerce Website Gadgetenterprises.com
Seamless Corporation (OTCBB: SMWF) announced that the Gadget Enterprises Team is proud to unveil the new, improved, and upgraded GadgetEnterprises.com website. The new site will be live Monday, October 5, at 12PM Pacific.
Several of the NEW features of GadgetEnterprises.com include:
* Enhanced Product Listings;
* Weekly updates on new products and special offers;
* Calendar of Dr. Gadget appearances;
* and much, much more to come.
Albert R. Reda, Chairman and President of Seamless Corporation, stated, "We are very excited about the new site, the Cruzin Cooler contest, and the upcoming race events and the new TV and Radio appearance that Dr. Gadget will be making over the coming months on behalf of the new website. Dr. Gadget is a popular TV and Radio personality and we are already experiencing the impact of Dr. Gadget's association with the company."
www.gadgetenterprises.com is currently approved to sell the Cables Unlimited products which include the Audios Unlimited Poolpod, and the Cruzin Cooler product line.
ABOUT DR. GADGET
Dr. Gadget appears regularly on EXTRA with Mario Lopez and on ABC's THE VIEW and he was recently featured on GSN's 2009 Game Show Award hosted by Howie Mandel.
PRECISION PETROLEUM CORPORATION (OTCBB: PPTO)
"Up 50.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/PPTO.php
Precision Petroleum Corporation is an independent energy company engaged in the acquisition, exploration and development of oil and natural gas properties in the
PPTO News:
October 5 - Precision Petroleum Corporation Increases Working Interest in the Sharon No. 1 Well,
Precision Petroleum Corporation (OTCBB: PPTO) President Richard Porterfield has advised that, based on a recent geological and engineering survey of the Oil Creek Sandstone in Section 5 of T3N - R1E, Gavin County, Precision has elected under the previous agreement to increase its working interest in Sharon No. 1.
Porterfield mentions that the well information provides a strong indication of maximum porosity in the Sandstone. Accordingly the well will be re-entered to magnify the exposure of this formation to several times of the present open whole access. The Oil Creek Sandstone is recognized by industry as a prolific oil producing zone in
Early this summer, Precision Petroleum advised that it would embark on an aggressive program to evaluate the technical potentials of the
LEFT BEHIND GAMES INCORPORATED (OTCBB: LFBG)
"Up 35.71% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/LFBG.php
Left Behind Games, Inc. engages in the development, publishing, and distribution of video games and related products in the
LFBG News:
October 5 - Skymark Research Initiates Independent Research Coverage On Left Behind Games, Inc.
Skymark Research, a leading provider of small- and micro-cap independent investment research, has initiated coverage on Left Behind Games, Inc. (OTCBB: LFBG). Skymark Research is currently offering a complimentary trial subscription. To view the company’s research, visit www.skymarkresearch.com.
AVI BIOPHARMA INCORPORATED (NASDAQ: AVII)
"Up 23.08% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/AVII.php
AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up-and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola
AVII News:
October 5 - AVI BioPharma Receives Expanded Contract From
$11.5 Million New Funding Brings Total Award to $45 Million
AVI BioPharma, Inc. (Nasdaq: AVII), a developer of RNA-based drugs, announced that it has received expanded contract funding of approximately $11.5 million from the Defense Threat Reduction Agency's (DTRA) Transformational Medical Technologies Initiative (TMTI) to support development of the Investigational New Drug (IND) data package for its candidate drug, AVI-7012, to treat Junin virus infection. To date, the United States Department of Defense (DoD) has contracted with AVI for work potentially worth up to $45 million for the development of AVI's RNA-based drug candidates to treat Ebola,
"AVI has recently been able to confirm the impressive and dose-related survival of drug-treated non-human primates in large dose titration studies for Ebola and Marburg virus infections, which were carried out in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)," said Dr. Patrick Iverson, Senior Vice President for Strategic Alliances at AVI. "Importantly, these studies allowed us to unequivocally demonstrate the sequence-specific nature of the protection afforded by our drug candidates."
AVI has received a 'safe to proceed' allowance from the United States Food and Drug Administration (FDA) for IND applications for clinical safety trials of its two lead products to treat Ebola and Marburg virus infections. These INDs represent the first TMTI supported drug candidates targeting bioterrorism agents to receive
AVI plans to conduct the animal efficacy trials for potential approval of its drugs under the Animal Rule as part of its continued collaboration with USAMRIID. The majority of the collaborative research effort between AVI and USAMRIID has been supported by a research contract from the DoD's TMTI with the goal of developing a new antiviral platform targeting hemorrhagic fever viruses. The current funding is a second amendment and expansion of an original contract from DTRA, which was awarded in November 2006 for $28 million and has been fully authorized. The contract for the first amendment was issued in May 2009 when an additional $5.9 million was authorized to support continued development of AVI's RNA-based drugs AVI-6002 and AVI-6003 to treat Ebola and
"The expansion of the contract for our therapeutic programs in Junin, Ebola and Marburg viruses reflects the DoD's continued support of our bio-defense program, which is developing a series of RNA-based anti-viral drugs," said David Boyle, Chief Financial Officer of AVI. "AVI's ability to virtually double the value of the original contract is a powerful illustration of the performance of our drug candidates to date."
AVI-6002, AVI-6003 and AVI-7012 are novel analogs based on AVI's PMO antisense chemistry in which anti-viral potency is enhanced by the addition of positively-charged components to the morpholino oligomer backbone.
ABOUT DTRA & TMTI
DTRA was founded in 1998 to integrate and focus the capabilities of the DoD that combat the weapons of mass destruction (WMD) threat. The mission of the DTRA is to safeguard
The TMTI was created by the DoD to protect the Warfighter from emerging and genetically altered biological threats by discovering and developing a wide range of medical countermeasures through enhanced medical research, development, test and evaluation programs. The TMTI Program Office is matrixed from the Joint Science and Technology Office — DTRA and Joint Program Executive Office — Chemical and Biological Defense, with oversight from the Office of the Secretary of Defense.
ABOUT USAMRIID
USAMRIID, located at
OTCPicks.com is located at
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure: OTCPicks.com has been compensated two thousand five hundred dollars by a third party (Blue Wave Advisors) for PPTO advertising and promotional services.
